FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220761318> ?p ?o ?g. }

• W4220761318 endingPage "22" @default.
• W4220761318 startingPage "18" @default.
• W4220761318 abstract "Goal. To evaluate the safety profile of onasemnogene abeparvovec (Zolgensma®) gene therapy in children with spinal muscular atrophy (SMA) in real clinical practice. Materials and methods. The study included 30 SMA children who underwent gene replacement therapy with onasemnogene abeparvovec (Zolgensma®) from December 2020 to December 2021 at the Center for Pediatric Psychoneurology. All children had a diagnosis of SMA confirmed by molecular genetic methods, with no more than 3 copies of the SMN2 gene and the absence of antibodies to the adeno-associated virus serotype 9. The safety profile was assessed by monitoring the clinical and laboratory data of the patients after administration of onasemnogene abeparvovec. Clinical events included all changes in the child’s condition that could be associated with the administration of the drug (hyperthermia, decreased appetite, nausea, vomiting, stool disorders). Laboratory assessment included monitoring of complete blood count, biochemical blood tests, blood coagulation indices. The degree of laboratory changes was estimated according to common terminology criteria for adverse events (CTCAE version 5.0). Results. The safety profile of the drug Zolgensma® was studied in 30 children aged from 3 to 39 months, with a weight of 5.2 kg to 14.2 kg. Twenty-eight (93.3%) children had at least one clinical event associated with the administration of the drug. Hyperthermia was observed in 24 (80%) children, nausea and vomiting in 18 (60%) children, decreased appetite in 20 (66.7%) children, stool changes in 4 (13.3%) children. Monitoring of laboratory indices revealed thrombocytopenia and monocytosis in twenty-two (73.3%) children and neutropenia in twelve (40%) children in the general blood test. An increase in the level of transaminases was noted in all children, the CTCAE grade 1 was detected in fifteen (50%) children, the CTCAE grade 2 in 7 (23.3%) children, CTCAE grade 3 in 6 (20%) children, CTCAE grade 4 in 2 (6.7%) children. Children with CTCAE grade 3 required correction of the prednisone dose up 2 mg/kg per day for 2-4 weeks. Two children with CTCAE grade 4 required pulse therapy with methylprednisolone at a dose of 30 mg/kg per day. Regardless of the level of transaminases, no change in the level of total and direct bilirubin was observed in any case. A decrease in prothrombin time was observed in 14 (46.6%) children. An increase in the level of troponin I was detected in four (13.3%) children. In all cases of serious adverse events, according to laboratory indices, the clinical condition of the children remained stable. The average duration of prednisone intake was 17.8 ± 6.6 weeks. Conclusion. The safety profile of the drug onasemnogene abeparvovec (Zolgensma®) in real clinical practice in children with SMA is presented." @default.
• W4220761318 created "2022-04-03" @default.
• W4220761318 creator A5001346475 @default.
• W4220761318 creator A5027783305 @default.
• W4220761318 creator A5034179120 @default.
• W4220761318 creator A5053288421 @default.
• W4220761318 creator A5053902941 @default.
• W4220761318 creator A5054185538 @default.
• W4220761318 creator A5057891996 @default.
• W4220761318 creator A5085285855 @default.
• W4220761318 date "2022-03-15" @default.
• W4220761318 modified "2023-09-26" @default.
• W4220761318 title "Safety profile of onasemnogene abeparvovec in children with spinal muscular atrophy" @default.
• W4220761318 cites W1980477780 @default.
• W4220761318 cites W1980537418 @default.
• W4220761318 cites W2068087221 @default.
• W4220761318 cites W2081735313 @default.
• W4220761318 cites W2143197369 @default.
• W4220761318 cites W2765253110 @default.
• W4220761318 cites W2987746715 @default.
• W4220761318 cites W3002862034 @default.
• W4220761318 cites W3080552198 @default.
• W4220761318 cites W3126267158 @default.
• W4220761318 cites W3174155996 @default.
• W4220761318 cites W3199905728 @default.
• W4220761318 cites W4205351576 @default.
• W4220761318 cites W4212907176 @default.
• W4220761318 cites W4226170144 @default.
• W4220761318 doi "https://doi.org/10.46563/1560-9561-2022-25-1-18-22" @default.
• W4220761318 hasPublicationYear "2022" @default.
• W4220761318 type Work @default.
• W4220761318 citedByCount "0" @default.
• W4220761318 crossrefType "journal-article" @default.
• W4220761318 hasAuthorship W4220761318A5001346475 @default.
• W4220761318 hasAuthorship W4220761318A5027783305 @default.
• W4220761318 hasAuthorship W4220761318A5034179120 @default.
• W4220761318 hasAuthorship W4220761318A5053288421 @default.
• W4220761318 hasAuthorship W4220761318A5053902941 @default.
• W4220761318 hasAuthorship W4220761318A5054185538 @default.
• W4220761318 hasAuthorship W4220761318A5057891996 @default.
• W4220761318 hasAuthorship W4220761318A5085285855 @default.
• W4220761318 hasConcept C126322002 @default.
• W4220761318 hasConcept C187212893 @default.
• W4220761318 hasConcept C197934379 @default.
• W4220761318 hasConcept C2778558090 @default.
• W4220761318 hasConcept C2779134260 @default.
• W4220761318 hasConcept C2780580376 @default.
• W4220761318 hasConcept C2780852908 @default.
• W4220761318 hasConcept C71924100 @default.
• W4220761318 hasConceptScore W4220761318C126322002 @default.
• W4220761318 hasConceptScore W4220761318C187212893 @default.
• W4220761318 hasConceptScore W4220761318C197934379 @default.
• W4220761318 hasConceptScore W4220761318C2778558090 @default.
• W4220761318 hasConceptScore W4220761318C2779134260 @default.
• W4220761318 hasConceptScore W4220761318C2780580376 @default.
• W4220761318 hasConceptScore W4220761318C2780852908 @default.
• W4220761318 hasConceptScore W4220761318C71924100 @default.
• W4220761318 hasIssue "1" @default.
• W4220761318 hasLocation W42207613181 @default.
• W4220761318 hasOpenAccess W4220761318 @default.
• W4220761318 hasPrimaryLocation W42207613181 @default.
• W4220761318 hasRelatedWork W1980872763 @default.
• W4220761318 hasRelatedWork W2034199439 @default.
• W4220761318 hasRelatedWork W2041128529 @default.
• W4220761318 hasRelatedWork W2164530441 @default.
• W4220761318 hasRelatedWork W2358248846 @default.
• W4220761318 hasRelatedWork W2375945238 @default.
• W4220761318 hasRelatedWork W2384102814 @default.
• W4220761318 hasRelatedWork W2391063887 @default.
• W4220761318 hasRelatedWork W243857094 @default.
• W4220761318 hasRelatedWork W3134060499 @default.
• W4220761318 hasVolume "25" @default.
• W4220761318 isParatext "false" @default.
• W4220761318 isRetracted "false" @default.
• W4220761318 workType "article" @default.